Craneware plc, a leader in healthcare financial performance solutions, announced its unaudited interim results for the six months ended 31 December 2025 (H1 FY26). The company reported strong financial performance with double-digit growth in adjusted EBITDA and EPS, driven by a 6% increase in group revenue to $105.7 million. Adjusted EBITDA rose by 10% to $33.4 million, and adjusted profit before tax increased by 14% to $23.5 million. Statutory profit before tax saw a significant 29% rise to $13.0 million, while adjusted basic EPS grew by 16% to 58.7 cents.
Key highlights include
**Revenue Growth and Customer Expansion**: Craneware achieved a 6% increase in group revenue, with new sales to New customers rising to 12% of total sales, up from 2% in H1 FY25. This reflects increased competitive take-out rates and future expansion opportunities.
**Healthy Financial Metrics**Net Revenue Retention (NRR) remained stable at 103% on a 12-month rolling basis, and customer retention rates exceeded 90%. Annual Recurring Revenue (ARR) grew by 4% to $184.2 million.
**Innovation and Partnerships**Investments in data and AI, including a partnership with Microsoft, have accelerated innovation. Major new functionality for the Trisus® platform is set to launch in H2, supporting medium-term growth ambitions.
**Strong Cash Position and Debt Reduction**: Cash reserves remained high at $71.2 million, and bank debt decreased by 26% to $23.4 million. The company also announced a $25 million share buyback program.
**Dividend Increase**The interim dividend was increased by 11% to 15.0 pence per share.
Cranewares CEO, Keith Neilson, expressed confidence in the companys outlook, citing high levels of expansion sales, healthy NRR, and an increasing 340B Shelter opportunity. The Board expects to deliver results for the year ending 30 June 2026 in line with market expectations.
The companys strategic focus on innovation, customer satisfaction, and partnerships, particularly with Microsoft, positions it well for continued growth in the evolving US healthcare market. Cranewares unique combination of deep healthcare expertise, proprietary data, and AI capabilities reinforces its role as a strategic partner for healthcare organizations.
**Summary**
Craneware plc reported robust H1 FY26 results with double-digit growth in adjusted EBITDA and EPS, driven by revenue increases, customer expansion, and innovation. The companys strong financial position, strategic partnerships, and focus on AI-driven solutions position it for continued success in the US healthcare market.